CN104829708A - 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 - Google Patents
一条d螺旋区突变的瘦素活性肽及其编码基因和应用 Download PDFInfo
- Publication number
- CN104829708A CN104829708A CN201510228121.6A CN201510228121A CN104829708A CN 104829708 A CN104829708 A CN 104829708A CN 201510228121 A CN201510228121 A CN 201510228121A CN 104829708 A CN104829708 A CN 104829708A
- Authority
- CN
- China
- Prior art keywords
- leptin
- fat
- peptide
- active peptide
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016267 Leptin Human genes 0.000 title claims abstract description 60
- 108010092277 Leptin Proteins 0.000 title claims abstract description 60
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 52
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 51
- 229940039781 leptin Drugs 0.000 title claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 54
- 210000001789 adipocyte Anatomy 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 13
- 150000001413 amino acids Chemical group 0.000 claims abstract description 10
- 230000008859 change Effects 0.000 claims description 34
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract description 24
- 230000004069 differentiation Effects 0.000 abstract description 19
- 229960004586 rosiglitazone Drugs 0.000 abstract description 12
- 239000013641 positive control Substances 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000593 degrading effect Effects 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000008685 targeting Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000786103 Steatomys pratensis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (3)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510228121.6A CN104829708B (zh) | 2015-05-06 | 2015-05-06 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
PCT/CN2015/088535 WO2016176933A1 (zh) | 2015-05-06 | 2015-08-31 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
JP2017540623A JP6486482B2 (ja) | 2015-05-06 | 2015-08-31 | Dへリックス領域での突然変異を有するレプチン活性ペプチド、そのコード遺伝子およびその応用 |
US15/805,071 US10342853B2 (en) | 2015-05-06 | 2017-11-06 | Leptin active peptide having D helix region mutations, coding gene thereof, and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510228121.6A CN104829708B (zh) | 2015-05-06 | 2015-05-06 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104829708A true CN104829708A (zh) | 2015-08-12 |
CN104829708B CN104829708B (zh) | 2017-11-28 |
Family
ID=53807939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510228121.6A Expired - Fee Related CN104829708B (zh) | 2015-05-06 | 2015-05-06 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10342853B2 (zh) |
JP (1) | JP6486482B2 (zh) |
CN (1) | CN104829708B (zh) |
WO (1) | WO2016176933A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016176933A1 (zh) * | 2015-05-06 | 2016-11-10 | 广东省昆虫研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
CN106749524A (zh) * | 2016-12-05 | 2017-05-31 | 华南理工大学 | 一种抗肥胖七肽npvwkrk |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066593A1 (fr) * | 2000-03-07 | 2001-09-13 | Biomolecular Engineering Research Institute | Coordonnee structurelle d'un complexe proteique et utilisation correspondante |
CN101544692A (zh) * | 2009-05-13 | 2009-09-30 | 广东省昆虫研究所 | 棕果蝠瘦素蛋白及其cDNA序列 |
CN101619101A (zh) * | 2009-05-13 | 2010-01-06 | 广东省昆虫研究所 | 马铁菊头蝠瘦素蛋白及其cDNA序列 |
WO2010117785A1 (en) * | 2009-03-31 | 2010-10-14 | Temple University - Of The Commonwealth System Of Higher Education | Leptin antagonist and methods of use |
CN102272163A (zh) * | 2008-12-05 | 2011-12-07 | 安吉奥开米公司 | 瘦素和瘦素类似物结合物及其用途 |
CN103694337A (zh) * | 2008-02-08 | 2014-04-02 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1406497A (en) * | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
WO1998012224A1 (en) * | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
AU782230B2 (en) * | 1999-09-22 | 2005-07-14 | Serono Genetics Institute S.A. | Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
BR112012026718A2 (pt) * | 2010-04-22 | 2017-12-19 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio. |
CN104829708B (zh) * | 2015-05-06 | 2017-11-28 | 广东省生物资源应用研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
-
2015
- 2015-05-06 CN CN201510228121.6A patent/CN104829708B/zh not_active Expired - Fee Related
- 2015-08-31 JP JP2017540623A patent/JP6486482B2/ja not_active Expired - Fee Related
- 2015-08-31 WO PCT/CN2015/088535 patent/WO2016176933A1/zh active Application Filing
-
2017
- 2017-11-06 US US15/805,071 patent/US10342853B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066593A1 (fr) * | 2000-03-07 | 2001-09-13 | Biomolecular Engineering Research Institute | Coordonnee structurelle d'un complexe proteique et utilisation correspondante |
CN103694337A (zh) * | 2008-02-08 | 2014-04-02 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
CN102272163A (zh) * | 2008-12-05 | 2011-12-07 | 安吉奥开米公司 | 瘦素和瘦素类似物结合物及其用途 |
WO2010117785A1 (en) * | 2009-03-31 | 2010-10-14 | Temple University - Of The Commonwealth System Of Higher Education | Leptin antagonist and methods of use |
CN101544692A (zh) * | 2009-05-13 | 2009-09-30 | 广东省昆虫研究所 | 棕果蝠瘦素蛋白及其cDNA序列 |
CN101619101A (zh) * | 2009-05-13 | 2010-01-06 | 广东省昆虫研究所 | 马铁菊头蝠瘦素蛋白及其cDNA序列 |
Non-Patent Citations (5)
Title |
---|
B.P.CUMMINGS: "Leptin therapy in type 2 diabetes", 《DIABETES, OBESITY AND METABOLISM》 * |
JEFFREY M. FRIEDMAN: "Leptin and the Regulation of Body Weight", 《THE KEIO JOURNAL OF MEDICINE》 * |
LEONORA NIV-SPECTOR等: "Identification of the hydrophobic strand in the A–B loop of leptin as major binding site III: implications for large-scale preparation of potent recombinant human and ovine leptin antagonists", 《BIOCHEMICAL SOCIETY》 * |
OSAMA ALSMADI等: "Leptin in Association With Common Variants of MC3R Mediates Hypertension", 《AMERICAN JOURNAL OF HYPERTENSION》 * |
YIYING ZHANG等: "Positional cloning of the mouse obese gene and its human homologue", 《NATURE》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016176933A1 (zh) * | 2015-05-06 | 2016-11-10 | 广东省昆虫研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
US10342853B2 (en) | 2015-05-06 | 2019-07-09 | Shanghai Yuanxin Biochemical Science And Technology Co. Ltd. | Leptin active peptide having D helix region mutations, coding gene thereof, and application thereof |
CN106749524A (zh) * | 2016-12-05 | 2017-05-31 | 华南理工大学 | 一种抗肥胖七肽npvwkrk |
CN106749524B (zh) * | 2016-12-05 | 2020-08-18 | 华南理工大学 | 一种抗肥胖七肽npvwkrk |
Also Published As
Publication number | Publication date |
---|---|
WO2016176933A1 (zh) | 2016-11-10 |
US20180050093A1 (en) | 2018-02-22 |
JP2018505180A (ja) | 2018-02-22 |
JP6486482B2 (ja) | 2019-03-20 |
CN104829708B (zh) | 2017-11-28 |
US10342853B2 (en) | 2019-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106754668A (zh) | 一种干细胞培养液及注射液 | |
CN108676073B (zh) | 一种抗肥胖十肽llvvypwtqr及其应用 | |
CN107541533A (zh) | 一种药食真菌菌丝多糖多肽免疫增强剂的制备方法 | |
CN110950925A (zh) | 具有修复营养激活细胞功能的ace抑制肽及制备方法 | |
CN104829708A (zh) | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 | |
CN104829707A (zh) | 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用 | |
CN115154356A (zh) | 一组胶原蛋白组合在制备抗衰老产品中的应用以及包括其的外用化妆品 | |
CN104694604A (zh) | 一种海马血管紧张素转化酶抑制肽的制备方法 | |
CN104829705A (zh) | 一条c螺旋区突变的瘦素活性肽及其编码基因和应用 | |
NO332272B1 (no) | Preparat med stimulerende aktivitet pa interleukin-6 produksjon, fremgangsmate for fremstilling av aktivt middel, samt stamme Rhodotorula SEBR 2002 | |
CN109081862A (zh) | 一种抗肥胖四肽pqtr及其应用 | |
CN113181231B (zh) | 具有增强巨噬细胞吞噬活性功能的组合物及其应用和免疫药物 | |
CN112851758B (zh) | 一种罗非鱼鳞促骨形成肽及其应用 | |
CN105505870B (zh) | 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途 | |
CN115124591A (zh) | 钝顶螺旋藻藻蓝蛋白血管紧张素转化酶抑制肽及其制备方法和应用 | |
CN100336500C (zh) | 补骨脂注射液的制备方法 | |
CN110386961B (zh) | 一种皮肤修复多肽rl-rl10及其应用 | |
CN113453674A (zh) | I型胶原蛋白或弹性蛋白的产生促进剂 | |
CN105919994B (zh) | 白术内酯iii在制备增强免疫功能的药物及保健品中的应用 | |
CN105085619B (zh) | 一种缢蛏活性十肽及其制备方法和应用 | |
CN113230287B (zh) | 灵芝和/或桦树茸在制备抗炎症因子产品、调控抗菌肽方面的用途 | |
CN106754629A (zh) | 一种五味子体细胞胚及其培养方法、培养基及应用 | |
KR20120058829A (ko) | 세콰이어 캘러스 추출물을 함유하는 지방유래 줄기세포의 줄기세포성 증진용 및 피부세포 증식용 조성물 | |
Lee et al. | Effects of Yukmigeehwang-hwan pharmacopuncture extracts on the collagenase activity and procollagen synthesis in HS68 human fibroblasts and tyrosinase activity | |
Ni et al. | Bioconversion of agriculture by-products with functionally enhanced Streptomyces sp. SCUT-3: Fish skin as a model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 510260 Xingang West Road, Guangdong, Guangzhou, No. 105, No. Applicant after: Guangdong Institute of biological resources application Address before: 510260 Xingang West Road, Guangdong, Guangzhou, No. 105, No. Applicant before: Guangdong Entomological Institute |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 510260 No. 105 West Xingang Road, Guangzhou, Guangdong, Haizhuqu District Patentee after: Institute of zoology, Guangdong Academy of Sciences Address before: 510260 No. 105 West Xingang Road, Guangzhou, Guangdong, Haizhuqu District Patentee before: Guangdong Institute of Applied Biological Resources |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171128 Termination date: 20210506 |
|
CF01 | Termination of patent right due to non-payment of annual fee |